Interferon Is Superior to Direct Acting Antiviral Therapy in Tertiary Prevention of Early Recurrence of Hepatocellular Carcinoma.
antiviral treatment
early recurrence
propensity score matching
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
19 Dec 2019
19 Dec 2019
Historique:
received:
19
11
2019
revised:
16
12
2019
accepted:
17
12
2019
entrez:
22
12
2019
pubmed:
22
12
2019
medline:
22
12
2019
Statut:
epublish
Résumé
The elimination of chronic hepatitis C infection (CHC) by pegylated interferon plus ribavirin (Peg-IFN/RBV) decreases hepatocellular carcinoma (HCC) recurrence rate. However, the tertiary prevention of HCC recurrence by direct acting antiviral agents (DAA) remains controversial. This study aims to compare the tertiary prevention effect between DAA and Peg-IFN/RBV in CHC-HCC patients. Three hundred and one patients who received curative HCC treatment were retrospectively recruited. The recurrence incidence rate (IR) was compared among patients either receiving Peg-IFN/RBV or DAA regimen or untreated by three timeframes (I: from HCC treatment to antiviral therapy; II: during antiviral therapy; III: after antiviral therapy). The prevention effect between Peg-IFN/RBV and DAA were compared in frame II and III after propensity score matching (PSM) with age, tumor staging, HCC treatment modality, and cirrhotic status. Before PSM, the recurrence IRs in three arms were comparable in frame I, while being lower in the Peg-IFN/RBV and DAA arm compared to the untreated arm in frame II. In frame III, the tertiary prevention effect lasted in the Peg-IFN/RBV arm (
Identifiants
pubmed: 31861706
pii: cancers12010023
doi: 10.3390/cancers12010023
pmc: PMC7016942
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Chang Gung Memorial Hospital, Linkou
ID : CMRPG3H0561
Organisme : Chang Gung Memorial Hospital, Linkou
ID : CORPG3H0671
Organisme : National Science Council
ID : MOST1072314B182A142
Déclaration de conflit d'intérêts
The authors have no financial and personal relationships with other people or organizations that could inappropriately influence (bias) their work.
Références
J Hepatol. 2016 Dec;65(6):1272-1273
pubmed: 27524465
Dig Liver Dis. 2018 Nov;50(11):1105-1114
pubmed: 30170908
Clin Exp Hepatol. 2017 Dec;3(4):194-197
pubmed: 29255807
Gastroenterology. 2019 May;156(6):1683-1692.e1
pubmed: 30660729
J Hepatol. 2018 Jul;69(1):182-236
pubmed: 29628281
J Hepatol. 2019 Jan;70(1):78-86
pubmed: 30336183
Aliment Pharmacol Ther. 2018 Jul;48(2):127-137
pubmed: 29851093
J Med Virol. 2019 Apr;91(4):650-658
pubmed: 30381831
Radiology. 2017 Nov;285(2):670-680
pubmed: 28562211
JAMA Oncol. 2017 Dec 1;3(12):1683-1691
pubmed: 28983565
Liver Cancer. 2017 Jun;6(3):204-215
pubmed: 28626732
J Hepatol. 2016 Oct;65(4):734-740
pubmed: 27288051
J Gastroenterol Hepatol. 2015 Jul;30(7):1197-204
pubmed: 25682720
J Hepatol. 2017 Dec;67(6):1204-1212
pubmed: 28802876
J Hepatol. 2018 Aug;69(2):461-511
pubmed: 29650333
World J Gastroenterol. 2007 Oct 21;13(39):5188-95
pubmed: 17876889
Gastroenterology. 2018 Nov;155(5):1436-1450.e6
pubmed: 30031138
Hepatology. 2018 Aug;68(2):449-461
pubmed: 29476694
J Hepatol. 2019 Aug;71(2):265-273
pubmed: 30959157
Ann Intern Med. 2013 Mar 5;158(5 Pt 1):329-37
pubmed: 23460056
J Hepatol. 2017 Jan;66(1):153-194
pubmed: 27667367
JAMA. 2012 Dec 26;308(24):2584-93
pubmed: 23268517
Anticancer Res. 2013 Aug;33(8):3317-25
pubmed: 23898098
J Hepatol. 2017 Nov;67(5):933-939
pubmed: 28627363
Antivir Ther. 2006;11(8):985-94
pubmed: 17302368
Liver Int. 2017 Aug;37(8):1122-1127
pubmed: 28423231
Clin Infect Dis. 2018 Oct 30;67(10):1477-1492
pubmed: 30215672
J Hepatol. 2016 Oct;65(4):727-733
pubmed: 27349488
Frontline Gastroenterol. 2018 Oct;9(4):262-270
pubmed: 30245788
Gastroenterology. 2019 Jun;156(8):2313-2329.e7
pubmed: 30836093
Hepatology. 2016 Nov;64(5):1818-1819
pubmed: 27136189
Semin Liver Dis. 2010 Feb;30(1):52-60
pubmed: 20175033
Gastroenterology. 2019 Jan;156(2):446-460.e2
pubmed: 30367836
Aliment Pharmacol Ther. 2017 Jan;45(1):160-168
pubmed: 27790734
Int J Cancer. 2017 Mar 1;140(5):1042-1049
pubmed: 27861842
J Viral Hepat. 2018 Jun;25(6):623-630
pubmed: 29274197
J Hepatol. 2017 Feb;66(2):338-346
pubmed: 27677714
Br J Cancer. 2016 Mar 29;114(7):744-50
pubmed: 27022825
Hepatology. 1999 Oct;30(4):889-93
pubmed: 10498639
J Hepatol. 2016 Oct;65(4):862-864
pubmed: 27255582
J Hepatol. 2017 Jan;66(1):236-237
pubmed: 27592303
Dig Dis Sci. 2017 Oct;62(10):2932-2942
pubmed: 28884320
J Gastroenterol Hepatol. 2016 Oct;31(10):1766-1772
pubmed: 26992142
J Gastroenterol Hepatol. 2011 Dec;26(12):1757-64
pubmed: 21615789
Ann Surg Oncol. 2017 Oct;24(11):3196-3202
pubmed: 28707053
Gastroenterology. 2016 Jul;151(1):130-139.e2
pubmed: 27039970
Eur J Gastroenterol Hepatol. 2005 Nov;17(11):1157-64
pubmed: 16215426
Br J Surg. 2016 May;103(6):725-734
pubmed: 27005482
J Natl Cancer Inst. 2008 May 21;100(10):698-711
pubmed: 18477802
J Viral Hepat. 2017 Dec;24(12):1160-1167
pubmed: 28643457
J Hepatol. 2016 Oct;65(4):719-726
pubmed: 27084592
Aliment Pharmacol Ther. 2017 Oct;46(7):688-695
pubmed: 28791711
J Hepatol. 2017 Oct;67(4):876-878
pubmed: 28733219